20CPR ORO 2.5MG

FARINGOTRICINA 2.5 MG ORODISPERABLE

active ingredients

A gold available tablet contains: thyrotric 2,5 mg. Excipients with known effects: glucose 20 mg, lactose 275 mg and sucrose 467 mg. For the full list of excipients, see paragraph 6.1.

Excellent

Menthol – Corn starch – Arabian rubber – Glucose – Lactose – Magnesium stearate – Saccarosius.

Therapeutic indications

Topic therapy of bacterial stomatitis.

Contraindications

Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1.

Population

Population Allow to slowly dissolve in mouth 1 tablet every 1⁄2 – 1 hour. Continue treatment for two or more days. Do not exceed the daily dosage of 10 tablets.

Conservation

This medicine does not require any special condition of conservation.

Warnings

The use, especially if prolonged, of the product can give rise to phenomena of sensitization. In this case it is necessary to stop the treatment and to establish an adequate therapy: similar treatment should be observed in case of development of nonsensical germ infections. Pediatric population In the early childhood the product should be administered in cases of actual need, under the direct control of the doctor. OTHER MEDICINAL PRODUCTS contains glucose, lactose and sucrose. Patients with rare hereditary problems of fructose intolerance, glucose–galactose mal absorption, or isomaltase sucrasis failure, should not take this medicine.

Interactions

No interactions with other medicines are known.

Effects

Because thyrotricin is poorly absorbed by mucous membranes, the possibility of allergic reactions is reduced. Rarely, language blackness, glossitis, awareness reactions may occur. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: www.agenziafarmaco.gov.it/it/responsabili.

Overdosing

There are no known overdose phenomena as the scarce absorption of thyrotrics through mucous membranes reduces the possibility of toxic phenologies at recommended doses.

In pregnant women and during breastfeeding the product should be administered in cases of actual need, under the direct control of the doctor.

Source: Farmadati